Currency In USD
| Previous Close | 5.68 |
| Open | 5.77 |
| Day High | 5.77 |
| Day Low | 5.17 |
| 52-Week High | 16.45 |
| 52-Week Low | 5.17 |
| Volume | 287,841.16 |
| Average Volume | 358,906 |
| Market Cap | 203.42M |
| PE | -1.32 |
| EPS | -3.96 |
| Moving Average 50 Days | 6.89 |
| Moving Average 200 Days | 9.36 |
| Change | -0.44 |
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
GlobeNewswire Inc.
Feb 17, 2026 12:00 PM GMT
-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 -- -- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2 data by end of year -- BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- En
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – -- Expects to initiate global Phase 1/2 MAD clinical study of ENTR-601-50 by the end of 2026 and to submit
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 17, 2025 12:00 PM GMT
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, Ja